GlobeNewswire Inc.··Century Therapeutics, Inc.Century Therapeutics Extends Cash Runway to 2029 Amid Pipeline Progress
Century Therapeutics reports $217M cash runway through Q1 2029, with lead diabetes therapy CNTY-813 targeting IND submission by late 2026.
IPSCclinical developmentType 1 diabetes